FDA 11月16日批准MYQORZO说明书更新:纳入MAPLE-HCM三期对照数据,24周峰值摄氧量主要终点达标、六项次要终点五项显著改善

Cytokinetics 公司11月16日宣布,美国食品药品管理局(FDA)已批准一项补充新药申请,把三期试验 MAPLE-HCM 的数据写入 MYQORZO(aficamten)的美国说明书。MYQORZO 是一种心肌肌球蛋白抑制剂,获批用于治疗有症状的梗阻性肥厚型心肌病(oHCM)成人患者,以改善运动能力与症状。
MAPLE-HCM 是一项三期、多中心、随机、双盲、双模拟对照试验,共入组175名成人患者,将 MYQORZO 与标准治疗β受体阻滞剂美托洛尔以单药形式头对头比较,主要终点为第24周峰值摄氧量(pVO2)较基线的变化。试验达到主要终点,且在各预设亚组中结果一致。
六项次要终点中五项显著改善,包括纽约心脏协会心功能分级、堪萨斯城心肌病问卷临床汇总评分、NT-proBNP、Valsalva 动作后左心室流出道梯度与左心房容积指数。两组不良事件总发生率相近;说明书数据显示,MAPLE-HCM 中高血压在 MYQORZO 组的发生率为15%,美托洛尔组为3%。
MYQORZO 最初于2025年12月获 FDA 批准。其美国说明书带有心力衰竭风险黑框警告,用药期间须按风险评估与缓解策略(REMS)计划做超声心动图监测。此次更新不新增适应症,只是把与美托洛尔的对照证据写入说明书。
图中是肥厚型心肌病的医学示意图,MYQORZO 获批治疗的正是梗阻性肥厚型心肌病。
FDA Approves MYQORZO Label Update on November 16: Phase 3 MAPLE-HCM Data Added, With the Week 24 Peak Oxygen Uptake Endpoint Met and Five of Six Secondary Endpoints Significantly Improved
Cytokinetics announced on November 16 that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application adding data from the Phase 3 MAPLE-HCM trial to the U.S. Prescribing Information for MYQORZO (aficamten). MYQORZO is a cardiac myosin inhibitor approved to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), to improve functional capacity and symptoms.
MAPLE-HCM was a Phase 3, multi-center, randomized, double-blind, double-dummy controlled trial enrolling 175 adults, comparing MYQORZO with the standard-of-care beta-blocker metoprolol, each as monotherapy, on peak oxygen uptake (pVO2). The trial met its primary endpoint of change in pVO2 from baseline to Week 24, with an effect consistent across all prespecified subgroups.
Five of six secondary endpoints improved significantly, including New York Heart Association Functional Class, the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score, NT-proBNP, post-Valsalva left ventricular outflow tract gradient and left atrial volume index. Overall adverse event rates were similar between groups; the label data show hypertension in 15% of patients on MYQORZO versus 3% on metoprolol in MAPLE-HCM.
MYQORZO was first approved by the FDA in December 2025. Its U.S. label carries a Boxed Warning for the risk of heart failure, and echocardiogram monitoring is required under a Risk Evaluation and Mitigation Strategy (REMS) program. The update adds no new indication; it places the head-to-head evidence against metoprolol into the label.
发布:GSM·美国(发布链接)
图片来源:Wikimedia Commons, File:Blausen 0166 Cardiomyopathy Hypertrophic.png — Author: BruceBlaus / Blausen.com staff. Licensing: CC BY 3.0.
GSM Global · 本篇英文版 English edition of this story

